GlobalData’s latest report reveals that India accounted for only around 3 per cent of the market in APAC in 2024, due to ...

The last two decades have seen an increase in the use of biological over mechanical heart valve replacements. However, while ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

India’s transcatheter aortic valve replacement (TAVR) market is projected to grow at a compound annual growth rate of around 24% until 2033.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Larson's pause on Monday was initially attributed to adverse effects to medication. After more tests, doctors identified it ...

After a round of tests, it was determined that the cause of the brief pause in my speech was a complex partial seizure,” U.S. Rep. John Larson said.

Using hormone replacement therapy (HRT) to reduce cardiovascular risk during menopause remains a topic of debate. The ...

Connecticut Rep. John Larson (D) said Tuesday that he had a seizure on the House floor the previous day. “Yesterday, at around noon, I experienced a medical incident on the House floor, when my speech ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...